Skip to main content
HR 5805 113th Congress House

Andrea Sloan CURE Act

Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to expanding access for breakthrough drugs, and for other purposes.

Introduced: December 8, 2014 Introduced by: McCaul, Michael T. Republican · Texas See on congress.gov
Health Administrative law and regulatory proceduresAdministrative remediesAdvisory bodiesCongressional oversight
More subjectsShow fewer subjects
Consumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyExecutive agency funding and structureFood and Drug Administration (FDA)Government information and archivesGovernment studies and investigationsHealth care coverage and access
Sign in to write a letter Sign in to watch
This bill died when the 113th Congress ended
It never became law before the 113th Congress (2013–2014) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 12, 2014
Referred to the Subcommittee on Health.
Dec 8, 2014
Referred to the House Committee on Energy and Commerce.
Dec 8, 2014
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 12, 2014

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act - Amends the Federal Food, Drug, and Cosmetic Act to require the sponsor of a “breakthrough drug” (which is a drug that qualifies for expedited approval, is an infectious disease product, or qualifies the sponsor for a priority review voucher) to submit to the Secretary of Health and Human Services (HHS) and make available to the public a policy on requests for access to the drug for compassionate use, including the minimum criteria for consideration or approval of requests and the time needed to make a decision.

Requires a breakthrough drug sponsor to explain a denied request for compassionate use to the person who made the request.

Directs HHS to establish an Expanded Access Task Force. Requires the Task Force and the Government Accountability Office (GAO) to evaluate patient access to investigational drugs and make recommendations for improving access.

Directs HHS to finalize the draft guidance entitled “Expanded Access to Investigational Drugs for Treatment Use--Qs & As,” taking into account reports from the Task Force and GAO.
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5805: Andrea Sloan CURE Act. 113th Congress. Open America. https://openamerica.io/bill/113-HR-5805/
MLA
"H.R. 5805: Andrea Sloan CURE Act." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HR-5805/.
Bluebook (legal)
H.R. 5805, 113th Cong. (2026), https://openamerica.io/bill/113-HR-5805/.
Markdown link
[H.R. 5805: Andrea Sloan CURE Act](https://openamerica.io/bill/113-HR-5805/)
Report a problem